[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"metabolism\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:metabolism":32},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,18,0,[8,52,78,112,147,169,205,227,250,282,313,337,370,399,435,463,488,542],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":21,"targetDuration":4,"studyType":24,"phases":25,"briefSummary":27,"conditions":28,"keywords":35,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":40,"lastUpdatePostDateStruct":41,"startDateStruct":44,"completionDateStruct":46,"leadSponsor":48,"locationsCount":51},"100540754","phase-2-vital-impact-improving-cardiometabolic-health-in-black-individuals-through-therapeutic-augmentation-of-cyclic-guanosine-mono-phosphate-signaling-pathway-100540754",false,"NCT06320951","VITAL-IMPACT: Improving Cardiometabolic Health in Black Individuals Through Therapeutic Augmentation of Cyclic Guanosine Mono-Phosphate Signaling Pathway","Improving Cardiometabolic Health in Black Individuals Through Therapeutic Augmentation of Cyclic Guanosine Mono-Phosphate Signaling Pathway","VITAL-IMPACT","Inclusion Criteria:\n\n* Adults: Age more than or equal to 18 years of age\n* Self-identified race\u002Fethnicity as African-American or Black\n* BMI ≥ 30 kg\u002Fm2\n* HOMA-IR ≥ 2.5\n* Blood pressure: 120-160\u002F80-100 mmHg (untreated or 1 week of washout in those treated with up to two classes of antihypertensives)\n* Willing to adhere to study protocol\n\nExclusion Criteria:\n\n* Women who are pregnant or breastfeeding or who can become pregnant and not practicing an acceptable method of birth control during the study (including abstinence)\n* Have any past or present history of cardiovascular diseases (stroke, myocardial infarction, heart failure, transient ischemic attack, angina, seizure or cardiac arrhythmia)\n* BP more than 160\u002F100 mmHg or those treated with three or more classes of antihypertensives\n* BMI \\>45 kg\u002Fm2\n* History of diabetes or fasting plasma glucose \\>=126 mg\u002FdL or HbA1C\\>=6.5% or prior treatment with antidiabetics\n* Estimated GFR \\\u003C 60 ml\u002Fmin\u002F1.73 m2; albumin-creatinine ratio ≥30 mg\u002Fg\n* Hepatic Transaminase (AST and ALT) levels \\>3x the upper limit of normal\n* Significant psychiatric illness (assessed using validated MINI questionnaire)\n* Anemia (men, Hb\\\u003C13 g\u002FdL; women, Hb \\\u003C12 g\u002FdL)\n* Inability to exercise on a treadmill",true,"ALL","18 Years","80 Years",{"count":22,"type":23},200,"ESTIMATED","INTERVENTIONAL",[26],"PHASE2","This study investigates the potential of vericiguat, a soluble guanylate cyclase stimulator, to improve cardiometabolic health in obese Black individuals with insulin resistance by directly enhancing cyclic guanosine monophosphate (cGMP) activity. Given that this population has been shown to have lower cGMP activity and the association of lower cGMP activity with increased cardiometabolic disease risk, the proposed study hypothesizes that augmenting cGMP activity in obese individuals will improve insulin sensitivity and energy expenditure. This study is a placebo-controlled randomized trial involving 200 Black obese participants with insulin resistance, assessing the effects of vericiguat on insulin sensitivity, resting, and exercise-induced energy expenditure over 12 weeks. Additionally, it will explore changes in brown adipose tissue and gene expression related to energy metabolism in white adipose tissue, aiming to provide insights into how increasing cGMP activity may improve cardiometabolic health in Black obese individuals.",[29,30,31,32,33,34],"Cardiovascular Diseases","Insulin Sensitivity\u002FResistance","Metabolic Disease","Metabolism","Energy Expenditure","Obesity",[33,36,37,38],"Insulin Sensitivity","African Americans","Cyclic Guanosine Monophosphate","NOT_YET_RECRUITING","2026-01-21",{"date":42,"type":43},"2026-01-23","ACTUAL",{"date":45,"type":23},"2026-12-01",{"date":47,"type":23},"2029-04-30",{"name":49,"class":50},"University of Alabama at Birmingham","OTHER",1,{"id":53,"slug":54,"hasResults":11,"nctId":55,"briefTitle":56,"officialTitle":56,"acronym":57,"eligibilityCriteria":58,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":59,"targetDuration":4,"studyType":24,"phases":61,"briefSummary":63,"conditions":64,"keywords":4,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":51},"100587637","tracing-of-real-time-glu13cose-metabolism-in-human-immune-cells-100587637","NCT06930976","Tracing Of Real-time glu13Cose Metabolism in Human Immune Cells","TORCH","Inclusion Criteria:\n\n* Adults aged 18 or older\n\nExclusion Criteria:\n\n* Pregnant\n* Prisoner or in police custody\n* Uncontrolled hyperglycemia\u002Fdiabetes\n* Current participation in another study where the total volume of blood drawn, when added to this study blood draw volume, exceeds 500cc in an 8 week period\n* Any medical issue or pharmacologic exposure which, in the opinion of the study investigator, that might interfere with the study objectives\n* Any reason which, in the opinion of the study investigator, adds additional risk to the participant",{"count":60,"type":23},12,[62],"NA","The purpose of this study is to understand how cells of the immune system use the common sugar glucose to fuel energy production and as a building block within the cell. Investigators will intravenously infuse a non-radioactive glucose tracer into participants over a few hours and collect immune cells from the blood to track uptake and usage of this glucose within these immune cells.",[65,32,66,67],"Glucose","Isotope Labeling","Immune System and Related Disorders","RECRUITING","2025-11-01",{"date":71,"type":43},"2025-11-04",{"date":73,"type":43},"2025-10-01",{"date":75,"type":23},"2027-06-30",{"name":77,"class":50},"Vanderbilt University Medical Center",{"id":79,"slug":80,"hasResults":11,"nctId":81,"briefTitle":82,"officialTitle":82,"acronym":83,"eligibilityCriteria":84,"healthyVolunteers":17,"sex":18,"minAge":85,"maxAge":86,"enrollmentInfo":87,"targetDuration":4,"studyType":24,"phases":89,"briefSummary":90,"conditions":91,"keywords":94,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":103,"lastUpdatePostDateStruct":104,"startDateStruct":106,"completionDateStruct":108,"leadSponsor":110,"locationsCount":51},"100592997","vital-vaccination-immunity-time-restricted-eating-aging-and-lifestyle-100592997","NCT07000708","VITAL: Vaccination, Immunity, Time-restricted Eating, Aging and Lifestyle","VITAL","Inclusion Criteria:\n\n* Male and female participants, enrolled in a 1:1 ratio\n* Age 60-85 years\n* Body mass index (BMI) 20-35 kg\u002Fm²\n* Capacity to give informed consent\n* Existing health insurance to allow evaluation and treatment of any incidental findings\n* Usual daily eating window \\> 11 hours\n* First meal of the day before 10:00 AM\n* Willingness to receive seasonal influenza and COVID-19 vaccination and proof of scheduled appointment\n* Willingness and ability to follow a prescribed TRE dietary regimen (8-hour daily eating window; 16-hour fast without any caloric intake)\n* Appointment for simultaneous influenza and COVID-19 vaccination pre-arranged with primary care physician and coordinated with study team to align with TRE intervention\n\nExclusion Criteria:\n\n* Any vaccination (especially influenza and\u002For COVID-19) within 6 months before the intervention start\n* Vaccinations not related to the study, administered during the study period from V0 to V4\n* History of influenza infection within 6 months prior to initiation of the study intervention\n* History of severe adverse reactions to prior vaccinations\n* Use of pharmacological weight-loss agents (e.g., semaglutide)\n* Diabetes mellitus under ongoing pharmacological treatment\n* Symptoms of systemic inflammatory or autoimmune disease\n* Immunosuppression (including use of immunosuppressive drugs)\n* Severe hypertension (systolic \\> 180 mmHg or diastolic \\> 110 mmHg)\n* Diseases or functional disorders which, in the opinion of the study physician, preclude participation in the study\n* Participation in any fasting intervention (e.g., TRE, alternate-day fasting, 5:2, 18:6) within 6 months before enrollment\n* Participation in another diet or weight-loss program (e.g., intensive athletic training)\n* Night-shift or rotating-shift work\n* Severe, active, or unstable medical conditions requiring treatment\n* Postoperative recovery phase\n* Antibiotic therapy within 3 months before enrollment\n* Acute or chronic infections\n* Therapeutic or medically prescribed special diets\n* Vegan diet\n* Current smoker\n* Weight change \\> 2 kg in the month before enrollment\n* Known substance, drug, or alcohol abuse\n* Anemia\n* Claustrophobia\n* Legal incapacity or any other circumstance that prevents full understanding of the nature, importance, and implications of the study","60 Years","85 Years",{"count":88,"type":23},24,[62],"The aim of this study is to investigate the effects of a four-week time-restricted eating (TRE) intervention on autophagy, immune function, and vaccine response to a seasonal influenza and COVID-19 vaccines in older healthy subjects.",[92,93,32],"Vaccination","Immunosenescence",[95,96,97,98,99,100,101,102],"fasting","vaccination","intermittent fasting","time-restricted eating","influenza","immunity","aging","immunosenescence","2025-09-17",{"date":105,"type":43},"2025-09-18",{"date":107,"type":43},"2025-09-10",{"date":109,"type":23},"2027-01",{"name":111,"class":50},"Charite University, Berlin, Germany",{"id":113,"slug":114,"hasResults":11,"nctId":115,"briefTitle":116,"officialTitle":117,"acronym":118,"eligibilityCriteria":119,"healthyVolunteers":11,"sex":120,"minAge":121,"maxAge":122,"enrollmentInfo":123,"targetDuration":4,"studyType":24,"phases":125,"briefSummary":126,"conditions":127,"keywords":130,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":138,"lastUpdatePostDateStruct":139,"startDateStruct":141,"completionDateStruct":143,"leadSponsor":145,"locationsCount":51},"100578589","glylo-supplement-pilot-trial-on-glycation-and-aging-in-postmenopausal-women-100578589","NCT06813261","GLYLO Supplement Pilot Trial on Glycation and Aging in Postmenopausal Women","A Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Pilot Trial Investigating the Impact of a Glycation Lowering (GLYLO) Supplement on Geroscience Outcomes in Postmenopausal Women","GRACE","Inclusion Criteria:\n\n1. Adults identified as female at birth with ovaries present (self-report)\n2. Post menopause \\>1y since last menses (self-report)\n3. Aged 45 - 65 y\n4. Anthropometric criteria (either of the following must be met):\n\n   * BMI ≥ 25 kg\u002Fm², based on self-reported weight and height\n   * OR Waist circumference ≥88 cm, based on self-measured values. Participants may provide average home weight measurements over two consecutive days if their BMI at the screening visit is slightly below 25 kg\u002Fm².\n5. HbA1c 5.5- 6.4% (screening measurement)\n6. Able to read and speak English well enough to provide informed consent and understand instructions.\n7. Able to attend in-person visits at The Buck Institute\n\nExclusion Criteria:\n\n1. Surgical menopause (self-report)\n2. Hysterectomy and\u002For ovariectomy (self-report)\n3. Receiving systematic hormone replacement therapy (HRT) (self-report). Use of local vaginal estrogen therapy (e.g., estrogen creams, vaginal tablets, or estrogen rings such as Estring) is permitted.\n4. Currently prescribed or received weight loss medications within the past 6 months or currently enrolled in a defined weight loss program. Weight must be stable (\\> 4%) within the last 3 months.\n5. Regular use of GLYLO, or regular use of a supplement containing any of the ingredients in GLYLO, within the last 3 months.\n6. Diabetes, T1DM or T2DM (self-report and screening tests): Treatment with any hypoglycemic agents (self-report), fasting glucose \\>125 mg\u002FdL (screening test; may reassess once), current use of hypoglycemic drugs for non-diabetic reasons (self-report).\n7. Elevated blood pressure readings (screening test): Resting Systolic Blood Pressure (SBP) ≥180 mmHg or resting Diastolic Blood Pressure (DBP) ≥100 mmHg. If a participant's blood pressure is elevated at the screening visit but not consistent with this threshold, they may provide home blood pressure readings (twice daily for two consecutive days) for the study team to evaluate eligibility.\n8. Psychotropic and\u002For other medications known to significantly impact weight unless on a stable dose for ≥ 6 months (self-report).\n9. Liver enzyme tests (alanine transaminase, aspartate transaminase) (screening test): \\>2 times the laboratory upper limit of normal. Reassessment during screening may be allowed under some conditions (e.g., recent use of acetaminophen).\n10. Immunosuppressive disorders, taking immunosuppressive medications (including oral prednisone \\>10mg\u002Fday and biological immunosuppressants), or receiving chemotherapy.\n11. Active gastrointestinal bleeding, or active bleeding diathesis (or resolved within 6 months prior to randomization) (self-report)\n12. Active peptic ulcer disease (or resolved within 6 months prior to randomization) (self-report)\n13. Active malignancy (or resolved within 6 months prior to randomization), except non-melanoma skin cancer not undergoing treatment (self-report).\n14. Active infection (or resolved within 1 month prior to randomization) (self-report)\n15. Allergy or hypersensitivity to any component of the supplement (self-report)\n16. History of hyperthyroidism or thyroid cancer(self-report), current abnormal thyroid function (blood test at screening).\n17. Cognitive status: Unable to provide informed consent to participate in and safely complete the protocol, as based on the judgment of the investigators (screening visit)\n18. Psychiatric status: any condition that might affect the ability to comply with the protocol in the opinion of the Clinical Investigator or Medical Officer (screening visit)\n19. Active eating disorders (self-report).\n20. Active diagnosis of Gout (self-report)\n21. Any change to prescription medications within 3 months prior to randomization that are judged by the study physician to impact the results of the study (self-report)\n22. No overnight hospitalization within 1 month prior to randomization (self-report)\n23. The presence of a condition or abnormality that in the opinion of the Investigator or Medical Officer would compromise the safety of the patient or the quality of the data","FEMALE","45 Years","65 Years",{"count":124,"type":23},30,[62],"The aim of this study is to assess the effectiveness of GLYLO, a dietary supplement, in postmenopausal women aged 45 to 65 who are overweight or obese and have elevated HbA1c levels. Specifically, the study seeks to evaluate whether GLYLO can reduce advanced glycation end products (AGEs) levels, which are harmful compounds formed when sugar attaches to proteins or fats in the body and can contribute to aging and disease. The primary outcome of the study is to determine if GLYLO reduces AGEs, enhances metabolic and hormonal health, and mitigates age-related functional decline.\n\nThis study includes one screening visit and three testing visits over a 6-month period. After eligibility is confirmed, participants will be randomly assigned to one of two groups to take either GLYLO (two capsules daily) or a placebo at home for 24 weeks. Participants will provide blood samples at every visit. During the three testing visits, they will complete physical performance and cognitive function tests, provide both blood and urine samples, and fill out quality of life and 24-hour dietary intake questionnaires. The dietary intake questionnaires will be completed only twice i.e. at the baseline visit and again at the final 6-month visit.",[128,32,129],"Postmenopause","Geroscience",[131,132,133,134,135,136,137],"Dietary supplement","Healthy aging","Women's health","Hormones","Advanced glycation end products (AGEs)","Glycation stress","Metabolic stress","2025-09-04",{"date":140,"type":43},"2025-09-08",{"date":142,"type":43},"2025-04-01",{"date":144,"type":23},"2026-06-30",{"name":146,"class":50},"Buck Institute for Research on Aging",{"id":148,"slug":149,"hasResults":11,"nctId":150,"briefTitle":151,"officialTitle":152,"acronym":153,"eligibilityCriteria":154,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":155,"targetDuration":4,"studyType":157,"phases":4,"briefSummary":158,"conditions":159,"keywords":4,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":160,"lastUpdatePostDateStruct":161,"startDateStruct":163,"completionDateStruct":165,"leadSponsor":167,"locationsCount":51},"100603824","caloric-balance-markers-study-100603824","NCT07141537","Caloric Balance Markers Study","Caloric Balance Markers (CaBooM) Study","CaBooM","Inclusion Criteria:\n\n* \\> 18 years of age\n* Able to travel to ISB for study visits.\n* Able to read and communicate in English.\n\nExclusion Criteria:\n\n* \\- Unable to provide informed consent.\n* Is a prisoner.",{"count":156,"type":23},400,"OBSERVATIONAL","The purpose of CaBooM is to identify and characterize biomarkers of caloric balance-the relationship between energy intake (calories consumed) and energy expenditure (calories burned).",[32],"2025-08-29",{"date":162,"type":43},"2025-09-03",{"date":164,"type":43},"2025-08-27",{"date":166,"type":23},"2033-08-31",{"name":168,"class":50},"Institute for Systems Biology",{"id":170,"slug":171,"hasResults":11,"nctId":172,"briefTitle":173,"officialTitle":174,"acronym":175,"eligibilityCriteria":176,"healthyVolunteers":17,"sex":18,"minAge":177,"maxAge":178,"enrollmentInfo":179,"targetDuration":4,"studyType":157,"phases":4,"briefSummary":181,"conditions":182,"keywords":187,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":196,"lastUpdatePostDateStruct":197,"startDateStruct":199,"completionDateStruct":201,"leadSponsor":203,"locationsCount":51},"100600324","studying-phenotypic-risks-for-obesity-and-underlying-traits-in-young-infants-100600324","NCT07096011","Studying Phenotypic Risks for Obesity and Underlying Traits in Young Infants","Studying Phenotypic Risks for Obesity and Underlying Traits in Young Infants: A Pilot Study","SPROUT","Inclusion Criteria:\n\n* Aged 2 weeks to less than 17 weeks at screening\n* Being fed human milk as a primary source of food\n* Be willing to consume one meal of infant formula\n* Be willing to complete a DXA measurement\n\nExclusion Criteria:\n\n* Unable to complete the screening visit and two clinic visits within 14 days\n* Born with health conditions that would render procedures unsafe\n* Born earlier than 35 days and 0 weeks gestation\n* Eating supplemental foods\n* Physician diagnosed feeding difficulties that may require a special type of nipple for bottle feeding","2 Weeks","16 Weeks",{"count":180,"type":23},40,"The purpose of this research study is to understand how infants metabolize different meals and to develop clinical tools which identify infants as having two different phenotypes. The phenotypes are the 1) metabolic \"thriftiness\" and 2) the metabolic flexibility.",[183,32,33,184,185,186],"Infant Body Composition and Metabolism","Infant Formula","Human Milk, Breast Milk","Metabolic Flexibility",[188,189,190,191,192,193,194,195],"infant","metabolism","energy expenditure","infant formula","breast milk","human milk","thrifty phenotype","metabolic flexibility","2025-08-21",{"date":198,"type":43},"2025-08-22",{"date":200,"type":43},"2025-07-28",{"date":202,"type":23},"2027-05",{"name":204,"class":50},"Pennington Biomedical Research Center",{"id":206,"slug":207,"hasResults":11,"nctId":208,"briefTitle":209,"officialTitle":209,"acronym":4,"eligibilityCriteria":210,"healthyVolunteers":11,"sex":18,"minAge":211,"maxAge":212,"enrollmentInfo":213,"targetDuration":4,"studyType":24,"phases":215,"briefSummary":216,"conditions":217,"keywords":4,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":218,"lastUpdatePostDateStruct":219,"startDateStruct":221,"completionDateStruct":223,"leadSponsor":225,"locationsCount":51},"100585819","the-impact-of-nicotinamide-mononucleotide-sustained-release-tablets-on-immunosenescence-and-metablism-in-middle-aged-and-elderly-individuals-with-metabolic-disorders-100585819","NCT06907329","The Impact of Nicotinamide Mononucleotide Sustained-release Tablets on Immunosenescence and Metablism in Middle-aged and Elderly Individuals With Metabolic Disorders.","Inclusion Criteria:\n\n1. Age 50-70 years with overweight or obesity (BMI 24kg\u002Fm2);\n2. At least one of the following three: metabolism-related fatty liver disease (diagnosed by ultrasound); pre-diabetes; type 2 diabetes mellitus with HbA1c \\\u003C7% without glucose-lowering drug therapy;\n3. Agreed to participate in the trial and could adhere to the follow-up and visit the hospital on their own; signed the informed consent form.\n\nExclusion Criteria:\n\n1. Patients with tumours;\n2. Patients with autoimmune diseases (excluding Hashimoto's thyroiditis);\n3. Severe cardiovascular disease or cardiac insufficiency;\n4. Systolic blood pressure \\> 160 mmHg or diastolic blood pressure \\> 100 mmHg;\n5. Chronic obstructive pulmonary disease;\n6. Chronic active hepatitis or cirrhosis;\n7. Chronic renal insufficiency;\n8. Stroke patients\n9. Severe haematological diseases;\n10. Infectious diseases;\n11. Mental illness;\n12. Other conditions that, in the opinion of the investigator, may affect the results of the study;\n13. Those who have used NMN or other anti-aging agents within six months.\n14. Premenopausal woman\n15. ALT, AST values are more than three times higher than the upper limit of the normal reference range","50 Years","70 Years",{"count":214,"type":23},126,[62],"The ageing of our country is increasing and the ageing of the population has led to a significant increase in aging related diseases. During the aging process of the organism, cellular senescence can occur in all systems of the body, of which the senescence of the immune system is called immunosenescence. Some studies have shown that metabolic disorders can also trigger aging. This study investigated the effect of nicotinamide mononucleotide (NMN) supplementation on immunosenescence in middle-aged and elderly people through a placebo-controlled long-range clinical trail, aiming to provide a new method to improve immunosenescence. The effects of NMN supplementation on glucose and lipid metabolic indexes, body composition and telomere length of peripheral blood cells are also investigated, which may open up new ideas for the prevention and treatment of glucose and lipid metabolic diseases.",[93,32],"2025-07-02",{"date":220,"type":43},"2025-07-08",{"date":222,"type":43},"2025-06-05",{"date":224,"type":23},"2027-03-31",{"name":226,"class":50},"Qing Su",{"id":228,"slug":229,"hasResults":11,"nctId":230,"briefTitle":231,"officialTitle":232,"acronym":4,"eligibilityCriteria":233,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":234,"targetDuration":4,"studyType":24,"phases":235,"briefSummary":236,"conditions":237,"keywords":240,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":242,"lastUpdatePostDateStruct":243,"startDateStruct":245,"completionDateStruct":247,"leadSponsor":249,"locationsCount":51},"100366758","phase-2-nautical-effect-of-natriuretic-peptide-augmentation-on-cardiometabolic-health-in-black-individuals-100366758","NCT04055428","NAUTICAL: Effect of Natriuretic Peptide Augmentation on Cardiometabolic Health in Black Individuals","The Effects of Natriuretic Peptide Augmentation on Cardiometabolic Health in Black Individuals (NAUTICAL)","Inclusion Criteria:\n\n* Adults: Age more than or equal to 18 years of age\n* Self-identified race\u002Fethnicity as African-American or Black\n* Blood pressure: 120-160\u002F80-100 mmHg\n\nExclusion Criteria:\n\n* Women who are pregnant or breastfeeding or who can become pregnant and not practicing an acceptable method of birth control during the study (including abstinence)\n* Have any past or present history of cardiovascular diseases (stroke, myocardial infarction, heart failure, transient ischemic attack, angina, or cardiac arrhythmia)\n* BP more than 160\u002F100 mmHg\n* BMI \\>45 kg\u002Fm2\n* History of diabetes or fasting plasma glucose \\>=126 mg\u002FdL or HbA1C\\>=6.5%\n* History of angioedema\n* Current or past (\\\u003C12 months) history of smoking\n* Estimated GFR \\\u003C 60 ml\u002Fmin\u002F1.73 m2; albumin-creatinine ratio ≥30 mg\u002Fg\n* Hepatic Transaminase (AST and ALT) levels \\>3x the upper limit of normal\n* Significant psychiatric illness or seizure disorder\n* More than 2 Alcoholic drinks daily\n* Anemia (men, Hct \\\u003C 38%, Hb\\\u003C13 g\u002FdL; women, Hct \\\u003C36%, Hb \\\u003C12 g\u002FdL)\n* Inability to exercise on a treadmill",{"count":22,"type":23},[26],"Black individuals are more likely to have decreased insulin sensitivity which results in a high risk for the development of cardiometabolic disease. The reasons for this are incompletely understood. Natriuretic peptides (NPs) are hormones produced by the heart that play a role in regulating the metabolic health of an individual. Low circulating level of NPs is an important contributor to increased risk for diabetes. The NP levels are relatively lower among Black individuals thus affecting their metabolic health and putting them at a higher risk for diabetes. This study aims to test the hypothesis that by augmenting NP levels using sacubitril\u002Fvalsartan, among Black Individuals one can improve their metabolic health (as measured by insulin sensitivity \\& energy expenditure) and help establish the role of NPs in the underlying mechanism behind increased risk for cardiometabolic disease in these population.",[238,29,30,31,239,32,33],"Diabetes Mellitus","Natriuretic Peptides",[239,241,36,33],"Diabetes","2025-07-01",{"date":244,"type":43},"2025-07-03",{"date":246,"type":43},"2020-08-15",{"date":248,"type":23},"2027-05-31",{"name":49,"class":50},{"id":251,"slug":252,"hasResults":11,"nctId":253,"briefTitle":254,"officialTitle":254,"acronym":4,"eligibilityCriteria":255,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":256,"targetDuration":4,"studyType":24,"phases":258,"briefSummary":259,"conditions":260,"keywords":266,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":272,"lastUpdatePostDateStruct":273,"startDateStruct":275,"completionDateStruct":277,"leadSponsor":279,"locationsCount":281},"100418985","personalized-responses-to-dietary-composition-trial-3-100418985","NCT04735835","Personalized Responses to Dietary Composition Trial 3","Inclusion Criteria:\n\n* Enrolled in the commercial ZOE testing program\n* Any sex\n* Minimum 18 years of age (minimum 19 years of age in Alabama and Nebraska due to state laws)\n* Body mass index (BMI) of greater than or equal to 16.5 kg\u002Fm2.\n* Living in the continental US states, other than in New York (excluded from the ZOE testing product also as they are unable to access the dried blood spot service provided by Quest), or living in the UK\n* Able and willing to comply with the study protocol and provide informed consent.\n* Under care for chronic medical conditions (including eating disorders, type 1 diabetes, type 2 diabetes), and confirm they have checked with their primary care physician that this study is safe for them (US cohort only)\n\nExclusion Criteria:\n\n* Cannot safely eat the pre-made test meals which contain standard US ingredients, e.g. due to allergy or recent gastrointestinal surgery, or are unwilling to consume these foods.\n* Are pregnant.\n* Have had a heart attack (myocardial infarction), stroke\u002Ftransient ischemic attack (TIA), or major surgery in the last two months.\n* Are unable to read and write in English, as the ZOE app is only available in English.",{"count":257,"type":23},250000,[62],"The PREDICT 3 study will build on previous research in over 2,000 individuals to further refine machine learning models that predict individual responses to foods, with the aim of advancing precision nutrition science and individualized dietary advice. The study incorporates both standardized and controlled dietary intervention, for the purpose of testing postprandial responses to specific mixed meals, in addition to a free-living period with a dietary record for measuring responses to a large variety of meals consumed in a realistic context, where the role of external factors (e.g. exercise, sleep, time of day) on postprandial responses may be determined. For the first time this PREDICT study is built on top of a commercial product which will allow access to a much larger group of participants who are already collecting large amounts of data through digital and biochemical devices that can contribute to science.",[241,261,262,263,264,34,32,265],"Heart Diseases","Diet Habit","Diet Modification","Healthy","Microbial Colonization",[267,268,269,270,271],"Gut microbiome","Personalised nutrition","Machine learning","Postprandial metabolism","Metabolic health","2025-04-11",{"date":274,"type":43},"2025-04-16",{"date":276,"type":43},"2020-07-20",{"date":278,"type":23},"2030-01-01",{"name":280,"class":50},"Zoe Global Limited",2,{"id":283,"slug":284,"hasResults":11,"nctId":285,"briefTitle":286,"officialTitle":287,"acronym":288,"eligibilityCriteria":289,"healthyVolunteers":11,"sex":18,"minAge":4,"maxAge":290,"enrollmentInfo":291,"targetDuration":4,"studyType":157,"phases":4,"briefSummary":293,"conditions":294,"keywords":298,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":304,"lastUpdatePostDateStruct":305,"startDateStruct":307,"completionDateStruct":309,"leadSponsor":311,"locationsCount":51},"100574086","evaluation-of-blood-and-cardiac-protein-o-glcnacylation-levels-in-cardiac-surgery-in-children-100574086","NCT06754709","Evaluation of Blood and Cardiac Protein O-GlcNAcylation Levels in Cardiac Surgery in Children","Evaluation of the Levels of O-GlcNAcylation of Cardiac and Blood Proteins in Paediatric Cardiac Surgery and Identification of Therapeutic Targets","CardiOGlcNAc","Inclusion Criteria:\n\n* Age from 0 to 17 years at the time of sampling\n* Children undergoing CEC for cardiac surgery\n* Signed bio-collection consent\n\nExclusion Criteria:\n\n* Children with an infection\n* Children with fever\n* Children with an immune deficiency\n* Children with autoimmune disease\n* Children with metabolic disease\n* Children with haematological diseases\n* Children with a genetic disease\n* Unsigned consent\n* Refusal by parents or child","17 Years",{"count":292,"type":23},300,"Cardiac surgery requires the use of extracorporeal circulation (ECC). Age-related differences in inflammatory response, the greater susceptibility of immature organ systems to injury and the larger ratio of extracorporeal circuitry to patient size make younger and smaller patients more vulnerable to organ injury. The main problem associated with ECC in neonates and infants is the duration of ECC due to heavier surgeries leading to a prolonged inflammatory state resulting in capillary leak syndrome, low cardiac output syndrome and organ dysfunction, resulting in higher morbidity and mortality. The means of limiting this inflammatory response remain limited. Future studies should aim to address new post-ECC prophylactic targets to improve myocardial and endothelial function. Cardiac metabolism is an important area of research because it plays a central role in maintaining cardiac function under stress. The study of O-GlcNAcylation could therefore be an interesting therapeutic target, given the beneficial role of its stimulation in acute stress situations, as demonstrated in sepsis.",[295,296,32,297],"Cardiac Surgery","Extracorporeal Circulation; Complications","Low Cardiac Output",[299,300,189,301,302,303],"cardiac surgery","extracorporeal circulation","low cardiac output","O-GlcNAcylation,","systemic inflammatory response syndrome","2025-04-10",{"date":306,"type":43},"2025-04-13",{"date":308,"type":43},"2025-02-13",{"date":310,"type":23},"2035-01-31",{"name":312,"class":50},"Nantes University Hospital",{"id":314,"slug":315,"hasResults":11,"nctId":316,"briefTitle":317,"officialTitle":318,"acronym":319,"eligibilityCriteria":320,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":321,"targetDuration":4,"studyType":157,"phases":4,"briefSummary":323,"conditions":324,"keywords":4,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":328,"lastUpdatePostDateStruct":329,"startDateStruct":331,"completionDateStruct":333,"leadSponsor":335,"locationsCount":51},"100581310","treatment-of-sleep-apnea-to-improve-metabolic-health-100581310","NCT06848647","Treatment of Sleep Apnea to Improve Metabolic Health","Treatment of Sleep Apnea to Improve Metabolic Health - a Novel Approach to Unanswered Questions","GLYCOSACT","Inclusion Criteria:\n\n* Patients diagnosed with obstructive sleep apnea\n* Planned for CPAP treatment\n* 18 years and above\n\nExclusion Criteria:\n\n* Patient not wanting to participate in study\n* Non-Swedish speaking\n* Judged by physician as non-fit for study participation",{"count":322,"type":23},600,"Diabetes and prediabetes prevail among obstructive sleep apnea (OSA) patients. OSA and short sleep both detrimentally affect glycemic control regardless of obesity. With 1 in 10 adults having diabetes, 1 in 10 with prediabetes, and an estimated 600,000 affected by OSA in Sweden, attaining glycemic control is crucial. Though continuous positive airway pressure (CPAP) is the most effective treatment for OSA, its application lacks personalization, ignoring factors like comorbidities and sleep duration. Key unanswered questions regarding CPAP's impact on glycemic control include: 1) Does high CPAP adherence optimize glycemic control? 2) Should short sleep be addressed alongside OSA treatment for glycemic control? 3) Does long-term diabetes hinder CPAP's glycemic control efficacy? The purpose of this project is to enable precision health in CPAP treatment and producing a personalized treatment model for achieving glycemic control in patients with OSA, treated with CPAP. Taking advantage of a large unique patient cohort (600 patients followed over 18 months) with extensive and objective measures on CPAP adherence, OSA reduction, sleep duration, as well as information on comorbidities, anthropometric, lifestyle data, and a wide range of biomarkers related to glycemic control. This comprehensive approach and in-depth analysis will address these questions and generate a personalized treatment strategy for glycemic control in CPAP-treated OSA patients.",[325,32,326,327],"Sleep Apnea, Obstructive","CPAP","Patients Above 18 Years","2025-02-26",{"date":330,"type":43},"2025-02-27",{"date":332,"type":43},"2024-05-13",{"date":334,"type":23},"2028-12-31",{"name":336,"class":50},"Uppsala University",{"id":338,"slug":339,"hasResults":11,"nctId":340,"briefTitle":341,"officialTitle":342,"acronym":343,"eligibilityCriteria":344,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":122,"enrollmentInfo":345,"targetDuration":4,"studyType":24,"phases":347,"briefSummary":348,"conditions":349,"keywords":356,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":361,"lastUpdatePostDateStruct":362,"startDateStruct":364,"completionDateStruct":366,"leadSponsor":368,"locationsCount":51},"100546699","identifying-wearable-biomarkers-to-monitor-dietary-intake-100546699","NCT06398340","Identifying Wearable Biomarkers to Monitor Dietary Intake","Identifying Physiological Biomarkers for Monitoring Dietary Behaviours","FoodSense","Inclusion Criteria:\n\n* Male or female\n* Age between 18-65 years (inclusive)\n* Body mass index (BMI) of 18-30 kg\u002Fm2\n* Willingness and ability to give written informed consent.\n* Willingness and ability to understand, to participate and to comply with the study requirements\n\nExclusion Criteria:\n\n* Outside of specified age and BMI range\n* Chronic medical conditions including for eating disorders, diabetes, obesity, hypertension, cancer, acute infectious disease, renal disease, cardiovascular disease, and chronic gastrointestinal condition.\n* Taking part in another research study or donating any blood in the last 3 months",{"count":346,"type":23},10,[62],"Background: Measuring what people eat is a challenge in nutrition research. Traditional methods, like food diaries, rely on self-reporting of individuals, and suffer from poor accuracy and recall bias.\n\nAims: This project aims to identify physiological biomarkers related to food and energy intake, which may be used to develop an objective tool to estimate individuals' food intake in future. Eating behaviours are accompanied by significant physiological changes such as skin temperature, blood oxygen saturation, pulse rate etc. The investigators intend to investigate whether monitoring these physiological changes can help us estimate eating behaviour, such as meal size, eating speed, and duration of meals.\n\nStudy design: Ten healthy adults will be invited for two study visits at NIHR Imperial Clinical Research Facility. Each visit will last for approximately 2 hr. They will consume a high- and low-calorie meal designed by nutritional researchers in a randomised order. During eating events, the investigators will track their physiological changes via a bedside monitor and wearable sensors. Blood samples will be taken from participants to measure their glycaemic response. Associations between energy load, glycaemic response, and physiological changes will be investigated. Our findings may promote an accelerated development of a wearable tool for dietary assessment in future.",[350,32,351,352,353,354,355],"Energy Intake","Digestion","Wearables","Dietary Intake Assessment","Healthy Volunteers","Blood Glucose",[357,358,359,360],"Dietary intake monitoring","wearable sensors","digital health","blood glucose","2025-02-17",{"date":363,"type":43},"2025-02-18",{"date":365,"type":43},"2024-08-19",{"date":367,"type":23},"2025-07-31",{"name":369,"class":50},"Imperial College London",{"id":371,"slug":372,"hasResults":11,"nctId":373,"briefTitle":374,"officialTitle":375,"acronym":376,"eligibilityCriteria":377,"healthyVolunteers":17,"sex":120,"minAge":19,"maxAge":378,"enrollmentInfo":379,"targetDuration":4,"studyType":24,"phases":381,"briefSummary":382,"conditions":383,"keywords":389,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":391,"lastUpdatePostDateStruct":392,"startDateStruct":394,"completionDateStruct":396,"leadSponsor":398,"locationsCount":51},"100568593","the-effects-of-night-shift-work-on-health-across-the-menstrual-cycle-100568593","NCT06683248","The Effects of Night Shift Work on Health Across the Menstrual Cycle","The Effects of Night Shift Work on Health Across the Menstrual Cycle: a Pilot Study","MENSLEEP","Inclusion Criteria:\n\n\\- Healthy\n\nExclusion Criteria:\n\n* Use of hormonal contraceptives\n* Chronic disease\n* Regular use of nicotine\n* Use of medication\n* Consumes excessive amounts of alcohol or coffee","35 Years",{"count":380,"type":23},60,[62],"The study aims to investigate the effects of sleep deprivation on women's health across different phases of the menstrual cycle.",[384,385,386,32,387,388],"Sleep Deprivation","Menstrual Cycle","Brain Health","Microbiota","Immune System",[390],"Estrogen","2024-11-11",{"date":393,"type":43},"2024-11-14",{"date":395,"type":43},"2022-04-25",{"date":397,"type":23},"2025-12-31",{"name":336,"class":50},{"id":400,"slug":401,"hasResults":11,"nctId":402,"briefTitle":403,"officialTitle":404,"acronym":405,"eligibilityCriteria":406,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":407,"targetDuration":409,"studyType":157,"phases":4,"briefSummary":410,"conditions":411,"keywords":418,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":426,"lastUpdatePostDateStruct":427,"startDateStruct":429,"completionDateStruct":431,"leadSponsor":433,"locationsCount":51},"100488978","impact-of-very-high-protein-content-enteral-nutrition-formulas-on-critically-ill-multiple-trauma-patients-100488978","NCT05647135","ImpACt of Very High Protein Content Enteral nUtrition Formulas on Critically Ill MUltipLe trAuma paTiEnts","ImpACt of Very High Protein Content Enteral nUtrition Formulas on Protein Metabolism and Residual Gastric Volume in Critically Ill MUltipLe trAuma paTiEnts","ACCUMULATE","Inclusion Criteria:\n\n* Adult patients (\\>18 yrs) admitted to the ICU\n* Multiple trauma (Injury severity score \\> 18)\n* Intubation and mechanical ventilation upon admission in ICU or during the first 24 hours of admission, for at least 48 h\n\nExclusion Criteria:\n\n* Age \\\u003C 18 years\n* Pregnant women\n* Patients not intubated or not mechanically ventilated or receiving only non-invasive ventilation\n* Patients with enteral feeding contraindication 48 h after admission\n* Patients with recent gastrointestinal surgical intervention\n* Patients on chronic therapy with corticosteroids",{"count":408,"type":23},70,"8 Weeks","This prospective observational randomized study aims to determine energy, protein intake and gastrointestinal tolerance while using enteral nutrition formulas with very high protein content and enteral nutrition formulas with normal protein content.\n\n* Differences regarding achieving protein and calorie daily targets when using enteral nutrition formulas with different protein content\n* Differences regarding residual gastric volume when using enteral nutrition formulas with different protein content\n* Differences regarding body composition when using enteral nutrition formulas with different protein content",[32,412,413,414,415,416,417],"Trauma","Nutritional Deficiency","Protein Malnutrition","Gastroparesis","Muscle Loss","Calorie Malnutrition Protein",[419,420,421,422,423,424,425],"enteral nutrition","multiple trauma","energy target","protein target","body composition","gastric residual volume","enteral nutrition intolerance","2024-07-17",{"date":428,"type":43},"2024-07-22",{"date":430,"type":43},"2023-03-01",{"date":432,"type":23},"2024-12-01",{"name":434,"class":50},"Romanian Society for Enteral and Parenteral Nutrition",{"id":436,"slug":437,"hasResults":11,"nctId":438,"briefTitle":439,"officialTitle":440,"acronym":4,"eligibilityCriteria":441,"healthyVolunteers":17,"sex":18,"minAge":442,"maxAge":122,"enrollmentInfo":443,"targetDuration":4,"studyType":24,"phases":445,"briefSummary":446,"conditions":447,"keywords":449,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":454,"lastUpdatePostDateStruct":455,"startDateStruct":457,"completionDateStruct":459,"leadSponsor":461,"locationsCount":51},"100552014","rmr-monitoring-feasibility-and-acceptability-100552014","NCT06467578","RMR Monitoring Feasibility and Acceptability","Feasibility and Acceptability of 6-week Repeated Measures of Resting Metabolic Rate Using a Portable Indirect Calorimeter","Inclusion Criteria:\n\n* Age 19-65 years\n* Ability to read, understand, and speak in English\n* BMI over 18.5\n* Live within a 1-hour radius of UBCO\n* Sedentary or recreationally active, defined as: \\\u003C300-minutes per week of self-reported voluntary exercise at moderate intensity or greater over the past 12-weeks\n* Not currently pregnant or lactating, not planning to become pregnant in the next 12 weeks\n* Ability to attend two in-person sessions at UBCO\n* Ability and willingness to fast for 12 hours before each study day visit and at least once a week before completing RMR measures using the portable indirect calorimeter\n* Access to a mobile device (i.e., smartphone or tablet) with reliable Bluetooth and Wi-Fi connection for the 6 week study duration\n* If applicable:\n* For people who occasionally (i.e., \\\u003C1x\u002Fday) use cannabis (including cannabidiol-based products): ability and willingness to abstain from cannabis for two days prior to each study day visit, and the morning of each study visit.\n* For people who use cannabis daily: ability and willingness to continue to use the exact same amount of cannabis as they normally use for two days prior to each study day visit, the morning of each study visit (if applicable), and during the 6 week study duration.\n\nExclusion Criteria:\n\n* Current or previous major comorbidities, by self-report, including:\n* Cardiovascular disease\n* Diabetes (type 1, type 2, pervious gestational)\n* Cancer\n* Thyroid diseases\n* Human immunodeficiency virus or hepatitis B or C\n* Renal diseases\n* Polycystic ovary syndrome\n* Uncontrolled\u002Funtreated, by self-report:\n* Hypertension\n* Dyslipidemia\n* Sleep disorders\n* Severe depression\n* Any other condition that may affect energy balance\n* Currently or in the past six months:\n* Use of regular medication that may affect energy balance, or sleep\n* Regular use of tobacco or nicotine products\n* Starting any new prescription medication within two weeks of the first study day visit or planning to do so during the study\n* Working night shifts or traveling across more than two time zones within two weeks of and throughout the study\n* History of surgical procedure for weight loss at any time (e.g., gastroplasty, gastric bypass, gastrectomy or partial gastrectomy, adjustable banding, gastric sleeve); history of extensive bowel resection for other reasons\n* Current alcohol or substance abuse (score ≥ 15 on the Alcohol Use Disorders Identification Test (AUDIT) 32\n* Current or past history of eating disorders including anorexia nervosa, bulimia, binge eating disorder (self-report or score \\>20 on the Eating Attitudes Test - 26 (EATS-26) questionnaire) 33\n* Current symptoms of depression (score ≥ 10 on the Center for Epidemiological Studies Depression Scale, 10-item version (CES-D-10))34\n* Weight loss \\>5kg in past 12 weeks for any reason\n* Weight loss of \\>20 kgs in past 3 years for any reason\n* Degree or previous work experience (in the past 10 years) in fields highly related to energy balance (e.g., those exercise or nutrition)","19 Years",{"count":444,"type":23},20,[62],"Obesity is a leading risk factor for chronic diseases such as type 2 diabetes, cancer, and cardiovascular disease. Generic weight management programs that target dietary intake and physical activity have been shown to be ineffective in maintaining weight loss beyond a 6-month period. Personalizing weight management programs produces more weight loss than generic programs, possibly through improved self-efficacy (confidence in one's ability to control weight through behavior). One way to personalize diet goals for individuals is by resting metabolic rate (RMR; 'metabolism'). This study will explore adherence and satisfaction of 6-weeks repeated at-home measures of metabolism using a portable device in healthy adults with and without obesity. Relationships among adherence and satisfaction outcomes to health behavior variables will be explored using dietary recalls, exercise monitors and questionnaires. Investigators will conduct a 6-week, one-arm feasibility study in order to address these questions. Twenty men and women ages 19-65 will be recruited (up to n=25 participants), among which 10 participants will have a body mass index (BMI) of ≥30kg\u002Fm2 (classified as having obesity), and the remaining 10 participants will have a body mass index (BMI) of \\\u003C 29.9kg\u002Fm2 (classified as not having obesity). The baseline study visit will evaluate participant's anthropometric measures, RMR using the ParvoMedics TrueOne 2400 and Breezing indirect calorimeters, psychological and behavioural related parameters. An activPAL device will be provided to measure participant physical activity. Completion of a 3-day diet record following the baseline study visit, in which participants keep a record of all food and beverages consumed over 2 weekdays and 1 weekend, is required. Participants will be asked to use the Breezing device from home to measure their RMR one time\u002Fweek on the same day of the week (± one day) and at the same time each morning for six consecutive weeks following the baseline visit. A weekly Qualtrics survey will be sent to participants to monitor adherence. A follow-up visit after the six weeks will assess participant's body composition using a Dual X-ray Absorptiometry (DEXA), in addition to completion of a user satisfaction interview with a study team member for descriptive analysis. The measures taken at the baseline study visit will be repeated at the follow-up visit.",[32,34,448],"Weight Loss",[450,451,452,453],"resting metabolic rate","portable indirect calorimeter","feasibility","acceptability","2024-06-20",{"date":456,"type":43},"2024-06-24",{"date":458,"type":43},"2024-04-19",{"date":460,"type":23},"2025-04-30",{"name":462,"class":50},"University of British Columbia",{"id":464,"slug":465,"hasResults":11,"nctId":466,"briefTitle":467,"officialTitle":468,"acronym":469,"eligibilityCriteria":470,"healthyVolunteers":17,"sex":18,"minAge":121,"maxAge":122,"enrollmentInfo":471,"targetDuration":4,"studyType":24,"phases":473,"briefSummary":474,"conditions":475,"keywords":477,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":479,"lastUpdatePostDateStruct":480,"startDateStruct":482,"completionDateStruct":484,"leadSponsor":486,"locationsCount":51},"100517029","assessment-metabolic-flexibility-in-middle-aged-individuals-the-nutritional-impact-of-cheese-consumption-100517029","NCT06012227","Assessment Metabolic Flexibility in Middle-aged Individuals: The Nutritional Impact of Cheese Consumption","Assessment Metabolic Flexibility by Indirect Calorimetry and Circulating Metabolic Parameters in Middle-aged Individuals: The Nutritional Impact of Cheese From Extensive and Intensive Farming.","Kent'Erbas","Inclusion Criteria:\n\n* 45-65 years of age\n* BMI \\\u003C 27\n* waist-to-hip ratio female\\\u003C0.85; male \\\u003C 0.98\n\nExclusion Criteria:\n\n* metabolic diseases\n* Physical activity of competitive nature\n* Vegans and vegetarians\n* Intolerances and allergies to the foods under study",{"count":472,"type":23},105,[62],"The aim of the study will be to evaluate the impact of consumption of meat and dairy products from extensive or intensive farming on apparently healthy individuals aged between 45 and 65 years, a stage of life associated with reduced metabolic flexibility and changes in lipid metabolism.\n\nThe study will analyze:\n\n1. The transcription factor PPAR-α determined by the gene expression of PPAR-α in white blood cells, variations in circulating fatty acid metabolism, and the endocannabinoid system determined by circulating analysis of N-acylethanolamine (NAE), and 2-monoacylglycerols (2-MG);\n2. Metabolic flexibility, determined by indirect calorimetry in fasting condition during an incremental exercise;\n3. Body composition, determined by bioimpedance analysis, waist circumference, and waist-to-hip ratio.",[32,476],"Nutrition",[195,478],"lipid metabolism","2023-08-26",{"date":481,"type":43},"2023-08-30",{"date":483,"type":43},"2022-01-20",{"date":485,"type":23},"2026-12-20",{"name":487,"class":50},"University of Cagliari",{"id":489,"slug":490,"hasResults":11,"nctId":491,"briefTitle":492,"officialTitle":493,"acronym":494,"eligibilityCriteria":495,"healthyVolunteers":17,"sex":120,"minAge":19,"maxAge":121,"enrollmentInfo":496,"targetDuration":4,"studyType":24,"phases":497,"briefSummary":498,"conditions":499,"keywords":517,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":533,"lastUpdatePostDateStruct":534,"startDateStruct":536,"completionDateStruct":538,"leadSponsor":540,"locationsCount":51},"100439987","hiit-vs-mict-during-pregnancy-and-health-and-birth-outcomes-in-mothers-and-children-100439987","NCT05009433","HIIT vs MICT During Pregnancy and Health and Birth Outcomes in Mothers and Children","The Effect of Pre- and Postnatal High Intensity Interval Training and Moderate Intensity Continuous Training on Biological, Functional and Psychological Markers of Pregnancy Disorders and Non-communicable Diseases in Mothers and Offsprings","HIIT MAMA","Inclusion Criteria:\n\nCriteria: Inclusion Criteria:\n\nFor pregnant women:\n\n1. course of pregnancy allowing participation in physical activities adapted to pregnant women\n2. consent of the obstetric care provider to participate in the study tests and exercise classes;\n3. taking part in all diagnostic and control tests to assess selected biological, functional and psychological parameters at each trimester of pregnancy, during the puerperium and one year after childbirth;\n4. participant's consent to use data from the medical documentation on the course of childbirth and the assessment of the new-born, as well as the results of preventive examinations in children aged one, two, four and six, routinely performed according to the Polish pediatric care system;\n5. availability to participate in classes three times a week until the day of delivery;\n6. declaration of participation in postpartum classes at least once a week and self-completion of the exercise program according to written instructions prepared by the exercise specialist;\n7. women can participate in the exercise programs regardless of their level of fitness or exercise capacity, as well as the level of motor skills (based on the diagnostic exercise tests, the exercise program will be tailored to the individual needs and capabilities of a woman).\n\nFor nonpregnant women:\n\n1. nulliparous;\n2. lack of diagnosed infertility and other disorders of the reproductive system;\n3. taking part in all diagnostic and control tests to assess selected biological, functional and psychological parameters at indicated time points: before and after each of the 8-week exercise program during the first 8 months of the study and once every 3 months during the following twelve months of the study\n4. declaration of availability to participate in exercise classes three times a week for the first 8 months of the program (attendance at least 80% is required);\n5. declaration of participation in classes at least once a week and self-completion of the exercise program to the required 150 minutes of physical activity per week, according to the written guidelines prepared by the instructor, for the next 12 months of the program;\n6. women can participate in the exercise program regardless of their level of fitness or exercise capacity, as well as the level of motor skills (based on the diagnostic exercise tests, the exercise program will be tailored to the individual needs and capabilities of a woman).\n\nExclusion Criteria for Pregnant and Nonpregnant Women:\n\n1. contraindications to increased physical effort or to any of the diagnostic or control tests;\n2. allergies to materials used during diagnostic and control tests (e.g. nickel present in steel plates of vaginal electrodes, disinfectants);\n3. other conditions that, according to the researchers, will threaten the health or safety of the participants or will significantly affect the quality of the collected data.",{"count":322,"type":23},[62],"Regular exercise during pregnancy and postpartum leads to health benefits for mother and child. Inactivity during pregnancy and after delivery is now treated as risky behavior. Physically active pregnant women significantly less often suffer from, among others, gestational diabetes, excessive weight gain, lipids disorders, hypertension, preeclampsia, depressive symptoms, functional and structural disorders, including stress urinary incontinence, back pain or diastasis recti abdominis (DRA). Prenatal physical activity reduces the risk of premature delivery and miscarriage, fetal macrosomia, complications in labor or the risk of metabolic disorders in children.\n\nHigh-intensity interval training (HIIT) has become one of the most popular trends in the fitness sector. The effectiveness of HIIT on a number of health indicators has been proven in various populations but limited data are available on HIIT during pregnancy.\n\nThe first hypothesis is that the HIIT, implemented during pregnancy and after childbirth, as a stronger exercise stimulus, will have a better impact on selected biological and psychological parameters of mothers, as well as on selected health parameters of their children, compared to the MICT (moderate intensity continuous training). Therefore, it promises better preventive effects on pregnancy complications and ailments as well as non-communicable diseases occurring in these populations. In the second hypothesis, it was assumed that HIIT and MICT implemented during pregnancy and after childbirth, tailored to the specific needs of the perinatal period, will not differ in the effectiveness of maintaining normal functional parameters in women, including prevention of urinary incontinence, back pain, DRA, etc.\n\nPregnant women who apply for the study will be divided into three groups: those attending the HIIT, MICT or educational programs. During the study, the participants will be under standard obstetric care. As comparative groups, non-pregnant women will be also recruited.\n\nThe investigators will collect data on selected biological, functional and psychological parameters in the study women at each trimester of pregnancy, during the puerperium and one year after childbirth. The data from the medical documentation on the course of childbirth and the assessment of the new-born, as well as the results of preventive examinations in the study women's children aged one, two, four and six years will be also analyzed.",[500,501,502,503,504,505,32,506,507,508,509,510,511,512,513,514,515,516],"Pregnancy","Postpartum","Childbirth","Health Status","Physical Fitness","Noncommunicable Diseases","Diabetes Mellitus, Gestational","Pregnancy Induced Hypertension","Body Composition","Back Pain","Pain Threshold","Biomechanics","Pelvic Floor Disorders","Urinary Incontinence","Cognitive Function","Depression","Anxiety",[518,519,520,521,522,523,524,525,526,527,528,503,529,502,530,531,532],"Pregnant women","Prenatal care","Postpartum women","Postnatal care","Exercise","Physical activity","Exercise intervention","Educational intervention","Exercise test","High-intensity interval training","Moderate-intensity continuous training","Physical fitness","Birth outcomes","Infant","Child","2022-11-30",{"date":535,"type":43},"2022-12-02",{"date":537,"type":43},"2021-06-24",{"date":539,"type":23},"2031-08-31",{"name":541,"class":50},"Gdansk University of Physical Education and Sport",{"id":543,"slug":544,"hasResults":11,"nctId":545,"briefTitle":546,"officialTitle":547,"acronym":548,"eligibilityCriteria":549,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":550,"enrollmentInfo":551,"targetDuration":4,"studyType":24,"phases":553,"briefSummary":554,"conditions":555,"keywords":4,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":571,"lastUpdatePostDateStruct":572,"startDateStruct":574,"completionDateStruct":576,"leadSponsor":578,"locationsCount":51},"100462875","cancer-associated-muscle-mass---molecular-factors-and-exercise-mechanisms-100462875","NCT05307367","Cancer-associated Muscle Mass - Molecular Factors and Exercise Mechanisms","Identifying Molecular Factors Contributing to Cancer-associated Muscle Mass Loss and Providing Clinical Evidence for Exercise Mechanisms to Functionally Restore Muscle in Cancer","PANACEA","Inclusion Criteria, WP1+WP2X+WP2:\n\n* Men and women at or above the age of 18\n* Histological and radiological verified NSCLC (both squamous and adenocarcinoma) st. IIIb\u002FIV stage not eligible to concurrent chemo\u002Fradiation therapy as primary treatment\n* Referred for 1st line palliative anticancer therapy (platin based, immunotherapy, combined therapy or TKI), this goes for WP1 + WP2\n* Referred for palliative anticancer therapy (platin based, immunotherapy, combined therapy or TKI), for recurrent cancer, this goes only for WP2X.\n* Having a staging\u002Fbaseline CT within 4 weeks of initiation of treatment (PET\u002FCT are also allowed), or a baseline scan planned within the first week of treatment.\n* ECOG Performance Status 0-2\n* Having signed the informed consent form\n\nExclusion Criteria, WP1+WP2X+WP2:\n\n* Any other known malignancy requiring active treatment (prior cancer diagnosis is not some exclusion criteria if oncology-treatment is completed)\n* Local palliative radiotherapy as primary treatment\n* ECOG Performance status \\> 2\n* Physical disabilities excluding physical testing\n* Inability to understand Danish\n* Inability to understand scoring systems\u002Fpatient-reported outcome measures\n\nInclusion Criteria, WP3:\n\n* Men and women above the age of 18\n* Histological and radiological verified NSCLC (both squamous and adenocarcinoma) st. IIIb\u002FIV stage\n* ECOG Performance Status 0-2\n* Having signed the informed consent form.\n\nExclusion Criteria, WP3:\n\n* Any other known malignancy requiring active treatment (prior cancer diagnosis is not some exclusion criteria if oncology-treatment is completed)\n* ECOG Performance Status \\> 2\n* Physical disabilities excluding physical testing\n* Inability to understand Danish\n* Inability to understand scoring systems\u002Fpatient-reported outcome measures","100 Years",{"count":552,"type":23},144,[62],"Muscle mass loss is a common adverse effect of cancer. Muscle mass loss occurs with or without reduction in body weight. Cancer cachexia (CC) is the involuntary loss of body weight of \\>5% within 6 months and it occurs in 50-80% of patients with metastatic cancer.\n\nIt is estimated that CC is a direct cause of up to 30% of all cancer-related deaths. No treatment currently is available to prevent CC, likely because the chemical reactions that causes of this devastating phenomenon in unknown.\n\nNo treatment currently is available to prevent muscle mass loss in patients with cancer but is urgently needed as the reduced muscle mass and function is associated with impaired physical function, reduced tolerance to anticancer therapy, poor quality of life (QoL), and reduced survival. There is evidence of an interdependence between informal caregiver (e.g. spouse) and patient QoL. Thus, identifying caregiver distress and needs can potentially benefit QoL for patients with cancer cachexia. Despite the enormous impact on disease outcomes, it is not known why the loss of muscle mass and function occurs and very few studies have investigated the underlying molecular causes in humans. In particular, there is a severe lack of studies that have obtained human skeletal muscle and adipose tissue sample material. Such reference sample materials will be invaluable to obtaining in-depth molecular information about the underlying molecular causes of the involuntary but common muscle mass and fat mass loss in cancer.\n\nAt a whole body level, cancer cachexia is associated with reduced sensitivity to the hormone insulin, high levels of lipids in the blood, and inflammation. Within the skeletal muscle, the muscle mass loss is associated with elevated protein breakdown and reduced protein build-up while emerging, yet, limited data also suggest malfunction of the power plants of the cells called mitochondrions. The role of malnutrition and how it contributes to weight loss is understood only to the extent of the observed loss of appetite and the reduced food intake because of pain, nausea, candidiasis of the mouth, and breathlessness. Evidence is increasing that the environment of the intestinal system could be implicated in cancer cachexia, yet, the possible effect of cancer and the cancer treatment on the intestinal environment is not understood. Thus, large and as yet poorly understood details of this syndrome precede a later weight loss.\n\nExercise training could help restore muscle function and how the chemical reactions works in cancer. In healthy people, and patients with diabetes, cardiovascular disease, and obesity exercise potently improves health. Exercise has been thought to slow down the unwanted effects of cancer cachexia by changing the reactions mentioned above. Thus, there is a tremendous gap in our knowledge of how and if exercise can restore the cells power plants function, muscle mass, strength, and hormone sensitivity in human cachexic skeletal muscle. Tackling that problem and examining potential mechanisms, will enable us to harness the benefits of exercise for optimizing the treatment of patients with cancer.\n\nThe data will provide novel clinical knowledge on cachexia in cancer and therefore addressing a fundamental societal problem.\n\nThree specific aims will be addressed in corresponding work packages (WPs):\n\n* investigate the involvement of hormone sensitivity of insulin and measure the chemical reactions between the cells in patients with lung cancer (NSCLC) and describe the physical performance and measure amount of e.g. muscles and adipose tissue across the 1st type of cancer treatment and understand how that is related to the disease and how patients and informal caregiver feel (WP1).\n* find changes in the chemical reactions in skeletal muscle, adipose tissue (AT), and blood samples in these patients, to understand how to predict how the disease will develop (WP2).\n* measure changes of skeletal muscle tissue in response to exercise and see if it might reverse the hormone insensitivity and improve muscle signaling and function (WP3).\n\nThe investigators believe that:\n\n* the majority of patients with advanced lung cancer, at the time of diagnosis already are in a cachectic state, where they lose appetite, and have hormonal changes, and an overall altered chemical actions between the cells affecting both muscle mass and AT. The investigators propose that all this can predict how the disease will progress, and how patient- and informal caregiver fell and how they rate their quality of life.\n* lung cancer and the treatment thereof is linked with changes in the blood, the muscle tissues, and the adipose tissues, especially in patients experiencing cachexia, that could be targeted to develop new treatment.\n* exercise can restore the muscles and improve insulin sensitivity and improve the function of the cells power plants in patients with lung cancer-associated muscle problems.",[556,557,522,32,508,558,559,560,561,562,563,564,565,566,567,568,569,570],"Cachexia","Neoplasms","Insulin Resistance","Physical Functional Performance","Quality of Life","Sarcopenia","Caregivers","Adipose Tissue","Muscle, Skeletal","Patient Reported Outcome Measures","Gastrointestinal Microbiome","Proteomics","Lipidomics","Epigenomics","Mitochondria","2022-05-09",{"date":573,"type":43},"2022-05-16",{"date":575,"type":43},"2022-04-01",{"date":577,"type":23},"2028-01-01",{"name":579,"class":50},"University of Copenhagen"]